Media Statements

These AbbVie statements and notices detail our position on various topics. Read on to learn our point of view on specific health issues.

AbbVie’s Open Public Hearing Comments at FDA Arthritis Advisory Committee Meeting – July 12, 2016, for ABP 501

AbbVie Completes New Licensing Agreement to Address Growing Demand for HIV Treatments in Africa

AbbVie committed to HIV supply in South Africa

AbbVie Statement Regarding Pharmacy Solutions

Committed to Biologic Innovation

AbbVie Files Citizen Petition with U.S. Food and Drug Administration (FDA) Regarding Product Labeling for Biosimilars

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

AbbVie.com | Site map | Privacy policy | Terms of use

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?